Mersana raises $35m, names former Millennium president CEO

Seventeen-year Millennium Pharmaceuticals veteran Anna Protopapas began her first day as president and CEO of Mersana Therapeutics on 2 March with an announcement that the antibody-drug conjugate (ADC) specialist closed a $35m Series B venture capital round.

Seventeen-year Millennium Pharmaceuticals veteran Anna Protopapas began her first day as president and CEO of Mersana Therapeutics on 2 March with an announcement that the antibody-drug conjugate (ADC) specialist closed a $35m Series B venture capital round.

The money gives Cambridge, Massachusetts-based Mersana enough cash, on top of fees from ongoing ADC co-development partnerships, to initiate trials...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category